title: Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
abstract: The development of inhibitors is the most severe complication of treating hemophilia patients with Factor VIII or IX, and providing effective hemostasis for inhibitor patients is challenging. Patients with high responding inhibitors (titer >5 BU/mL) are usually treated with recombinant activated Factor VII (rFVIIa), 90-120 microg/kg every 2-3 hours, or plasma-derived activated prothrombin complex concentrate. The aim of this study was to assess the efficacy and safety of a single dose of 270 microg/kg rFVIIa in inhibitor patients with joint or soft tissue bleeds treated at the Department of Paediatric Hematology and Oncology and the Department of Hematology and Transplantology. 7 inhibitor patients (3 adults aged 23-33 and 4 children aged 3-14) were included in the study. The hemostatic efficacy and tolerability of a single high dose of rFVIIa for home treatment of moderate or severe bleeds was evaluated. Treatment with rFVIIa effectively stopped bleeding in all patients without any adverse events. In most cases a single dose of rFVIIa 270 microg/kg was more effective than 3 or 4 lower doses (90 microg/kg) and less traumatic for pediatric patients. Based on present studies, it can be concluded that a single dose of rFVIIa is effective and well tolerated in the treatment of intra-articular bleeds in patients with hemophilia complicated by the presence of inhibitors.
authors.affiliation: Department of Pediatrics Hematology and Oncology, Medical University of Warsaw, Warsaw, Poland. pawel.laguna@litewska.edu.pl
authors.forename: Paweł
authors.initials: P
authors.lastname: Łaguna
authors.forename: Andrzej
authors.initials: A
authors.lastname: Mital
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000008:administration & dosage* / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa